Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-25T06:12:55.509Z Has data issue: false hasContentIssue false
  • English
  • Français

An Appraisal of the Continuing Practice of Prescribing Tranquillizing Drugs for Long-stay Psychiatric Patients

Published online by Cambridge University Press:  29 January 2018

J. S. Hughes  and
J. Crawford Little
J. S. Hughes
Affiliation:
Storthes Hall Hospital, and St. Luke's Hospital, Huddersfield
J. Crawford Little
Affiliation:
Crichton Royal Hospital, Dumfries; St. James's Hospital, Leeds
Get access Rights & Permissions [Opens in a new window]

Extract

Few with relevant experience would dispute the common observation that a striking change for the better has taken place in the behaviour of long-stay patients in British psychiatric hospitals over the past fifteen years.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 113 , Issue 501 , August 1967 , pp. 867 - 873
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ayd, F. J. (1966). International Drug Therapy Newsletter, i, i. Baltimore.Google Scholar
Bell, G., Morrice, J. K., Ratcliff, R., Macrae, A. K., Imlah, N., Howieson, E., McPherson, J., Gordon, W. W., Holden, J. C., and Gibson, I. A. (1961). “Controlled trial of prochlorperazine (Stemetil) in schizophrenia.” J. ment. Sci., 107, 514–522.Google Scholar
Bock, R., and Swain, J. (1962). “Ophthalmological findings in patients on long-term chlorpromazine therapy.” Amer. J. Ophthal., 56, 808–810.Google Scholar
British Medical Journal (1964). Leading article: “Side effects of phenothiazine drugs.” Brit. med. J., ii, 1412.Google Scholar
Brooks, G. W. (1959). “Withdrawal from neuroleptic drugs.” Amer. J. Psychiat., 115, 931–932.CrossRefGoogle ScholarPubMed
Caffey, E. M., Diamond, L. S., Frank, T. V., Grasberger, J. C., Herman, L., Klett, C. J., and Rothstein, G. (1964). “Discontinuation or reduction of chemotherapy in chronic schizophrenics.” J. chron. Dis., 17, 347–358.Google Scholar
Diamond, L. S., and Marks, J. D. (1960). “Discontinuance of tranquillizers among chronic schizophrenic patients receiving maintenance dosage.” J. nerv. ment. Dis., 131, 247–251.Google Scholar
Fleming, B. G., and Currie, J. D. C. (1958). “Investigation of a new compound B.W. 203, and of chlorpromazine in the treatment of psychosis.” J. ment. Sci., 104, 749–757.CrossRefGoogle ScholarPubMed
Freeman, L. S., and Alson, E. (1962). “Prolonged withdrawal of chlorpromazine in chronic patients.” Dis. nerv. Syst., 23, 522–525.Google Scholar
Good, W. W., Sterling, M., and Holzman, W. H. (1958). “Termination of chlorpromazine with schizophrenic patients.” Amer. J. Psychiat., 115, 443–448.CrossRefGoogle ScholarPubMed
Hall, R. A., and Dunlap, D. J. (1955). “A study of chlorpromazine: methodology and results with chronic semi-disturbed schizophrenics.” J. nerv. ment. Dis., 122, 301–314.Google Scholar
Greiner, A. C., and Nicolson, G. A. (1964). “Pigment deposition in viscera associated with prolonged chlorpromazine therapy.” Canad. med. Ass. J., 91, 627–635.Google Scholar
Hamilton, M. (1965). “Ten years of chlorpromazine.” Comp. Psych., 6, 291–297.CrossRefGoogle ScholarPubMed
Hamilton, M., Smith, A. L. G., Lapidus, H. E., and Cadogan, E. P. (1960). “A controlled trial of thiopropazate dihydrochloride (Dartalan), chlorpromazine and occupational therapy in chronic schizophrenics.” J. ment. Sci., 106, 40–55.Google Scholar
Henderson, Sir D. K. (1964). The Evolution of Psychiatry in Scotland. Livingstone: Edinburgh.Google Scholar
Hollister, L. E., and Kosek, J. C. (1965). “Sudden death during treatment with phenothiazine derivatives.” J. Amer. med. Ass., 192, 1035–1038.Google Scholar
Hunter, R., Earl, C. J., and Thornicroft, S. (1964). An apparently irreversible syndrome of abnormal movements following phenothiazine medication.” Proc. roy. soc. Med., 57, 758–762.Google Scholar
Judah, L. N., Josephs, Z. M., and Murphree, O. D. (1961). “Results of simultaneous withdrawal of ataraxics in 500 chronic psychotic patients.” Amer. J. Psychiat., 118, 156–158.CrossRefGoogle ScholarPubMed
Little, J. C. (1958). “A double-blind controlled comparison of the effects of chlorpromazine, barbiturate and a placebo in 142 chronic psychotic in-patients.” J. ment. Sci., 104, 334–349.Google Scholar
Loftus, T. A., Clarke, D. L., Crouse, F. R., Dillon, T. E., Jones, D. J., and Lefevre, H. E. (1961). “Negative results with chlorpromazine, and benactyzine in a group of chronic schizophrenics, with critical evaluation of similar studies.” Psychiat. Quart., 35, 121–133.CrossRefGoogle Scholar
MacKeith, S. (1964). Personal communication.Google Scholar
Manhattan After-Care Clinic (1961). Report to Congress referred to in: Psychopharmacology Service Center Bulletin, U.S. Dept. of Health, Educ. and Welfare, Bethesda, 2 (3), 1962, p. 3.Google Scholar
Marjerrison, G. Irvine, D. Stewart, C. N., Williams, R., Matheu, H., and Demay, M. (1964). “Withdrawal of long-term phenothiazines from chronically hospitalized psychiatric patients.” Canad. psych. Ass. J., 9, (4), 290–298.Google Scholar
Mitchell, P. H. (1956). “Chlorpromazine in the treatment of the chronic disturbed schizophrenic patient.” J. ment. Sci., 102, 151–154.Google Scholar
Olson, G. W., and Peterson, D. B. (1960). “Sudden removal of tranquilizing drugs from chronic psychiatric patients.” J. nerv. ment. Dis., 131, 252–255.Google Scholar
Richardson, H. L., Graupner, K. I., and Richardson, M. E. (1966). “Intra-myocardial lesions in patients dying suddenly and unexpectedly.” J. Amer. med. Ass., 195, 254–260.Google Scholar
Rothstein, C. (1960). “An evaluation of the effects of discontinuation of chlorpromazine.” New Eng. J. Med., 262, 67–69.CrossRefGoogle ScholarPubMed
Rothstein, C. Zelterman, I., and White, H. R. (1962). “Discontinuation of maintenance doses of ataractic drugs on a psychiatric continued treatment ward.” J. nerv. ment. Dis., 134, 555–560.Google Scholar
Sarwer-Foner, G. J., and Ogle, W. (1956). “Psychosis and enhanced anxiety produced by reserpine and chlorpromazine.” Canad. med. Ass. J., 74, 526–532.Google Scholar
Shawver, J. R., Gorham, D. R., Leskin, L. W., Good, W. W., and Kabnick, D. E. (1959). “Comparison of chlorpromazine and reserpine in maintenance drug therapy.” Dis. nerv. Syst., 20, 452–457.Google Scholar
Trelles, J. O., and Saavedra, A. (1954). “Cura de sueno con largactil en al tratamiento de algunos desordenes mentales.” (“Sleep therapy with largactil in the treatment of various mental disorders.”) Rev. Neuro. Psiquiat., 17/2, 125–161.Google Scholar
Vaillant, G. E., Semrad, E. V., and Ewalt, J. R. (1964). “Current therapeutic results in schizophrenia.” New Eng. J. Med., 271, 280–283.Google Scholar
Walsh, G. P., Walton, D., and Black, D. A. (1959). “The relative efficacy of ‘Vespral’ and chlorpromazine in the treatment of a group of chronic schizophrenic patients.” J. ment. Sci., 105, 199–209.CrossRefGoogle ScholarPubMed
Whittaker, C. B., and Hoy, R. M. (1963). “Withdrawal of perphenazine in chronic schizophrenia.” Brit. J. Psychiat., 109, 422–427.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.